ThermoGenesis (THMO) 10-Q 15 May 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Mar. 31, 2014	12-May-14
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'CESCA THERAPEUTICS INC.	'
Entity Central Index Key	'0000811212	'
Current Fiscal Year End Date	'--06-30	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	32,641,379
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$6,575	$6,884
Accounts receivable, net of allowance for doubtful accounts of $39 ($47 at June 30, 2013)	5,560	4,898
Inventories	4,800	4,259
Prepaid expenses and other current assets	198	232
Total current assets	17,133	16,273
Equipment, less accumulated depreciation of $3,773 ($3,277 at June 30, 2013)	2,373	2,208
Goodwill	18,893	0
Intangible assets, net	8,684	0
Other assets	70	48
Total assets	47,153	18,529
Current liabilities:	'	'
Accounts payable	3,039	3,106
Accrued payroll and related expenses	676	477
Deferred revenue	520	377
Other current liabilities	1,250	1,188
Total current liabilities	5,485	5,148
Other noncurrent liabilities	434	63
Commitments and contingencies (Footnote 4)	'	'
Stockholders' equity:	'	'
Preferred stock, $0.001 par value; 2,000,000 shares authorized; none outstanding	0	0
Common stock, $0.001 par value; 80,000,000 shares authorized; 32,641,379 issued and outstanding (16,557,627 at June 30, 2013)	33	16
Paid in capital in excess of par	161,152	127,493
Accumulated deficit	-119,952	-114,191
Accumulated other comprehensive income	1	0
Total stockholders' equity	41,234	13,318
Total liabilities and stockholders equity	$47,153	$18,529

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, except Share data, unless otherwise specified
Current assets:	'	'
Accounts receivable, allowance for doubtful accounts	$39	$47
Equipment, accumulated depreciation	$3,773	$3,277
Stockholders' equity:	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	80,000,000	80,000,000
Common stock, shares issued (in shares)	32,641,379	16,557,627
Common stock, shares outstanding (in shares)	32,641,379	16,557,627

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) [Abstract]	'	'	'	'
Net revenues	$4,038	$4,892	$12,150	$13,816
Cost of revenues	2,502	3,218	7,434	8,540
Gross profit	1,536	1,674	4,716	5,276
Expenses:	'	'	'	'
Sales and marketing	687	733	2,115	2,124
Research and development	768	658	2,398	2,210
General and administrative	1,940	1,565	5,964	3,790
Gain on sale of product line	0	-161	0	-2,161
Total operating expenses	3,395	2,795	10,477	5,963
Loss from operations	-1,859	-1,121	-5,761	-687
Interest and other income (expense), net	0	0	0	-2
Net loss	-1,859	-1,121	-5,761	-689
Other comprehensive income:	'	'	'	'
Foreign currency translation adjustments	50	0	50	0
Comprehensive loss	($1,809)	($1,121)	($5,711)	($689)
Per share data:	'	'	'	'
Basic and diluted net loss per common share (in dollars per share)	($0.07)	($0.07)	($0.28)	($0.04)
Shares used in computing per share data (in shares)	28,430,676	16,526,232	20,592,099	16,521,462

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net (loss)	($5,761)	($689)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	587	400
Stock based compensation expense	462	410
Loss on disposal of equipment	0	7
Gain on sale of product line	0	-2,161
Net change in operating assets and liabilities:	'	'
Accounts receivable, net	-724	-384
Inventories	-430	994
Prepaid expenses and other current assets	84	0
Other assets	3	0
Accounts payable	-397	-1,071
Accrued payroll and related expenses	174	-17
Deferred revenue	129	-51
Other liabilities	-223	65
Net cash used in operating activities	-6,096	-2,497
Cash flows from investing activities:	'	'
Capital expenditures	-326	-342
Cash acquired in acquisition	351	0
Proceeds from sale of product line	0	2,535
Net cash provided by investing activities	25	2,193
Cash flows from financing activities:	'	'
Repayment of related party notes payable	-150	0
Exercise of options and warrants	21	0
Issuance of common stock	5,944	0
Repurchase of common stock	-68	-54
Net cash provided by (used in) financing activities	5,747	-54
Effects of foreign currency rate changes on cash and cash equivalents	15	0
Net decrease in cash and cash equivalents	-309	-358
Cash and cash equivalents at beginning of period	6,884	7,879
Cash and cash equivalents at end of period	6,575	7,521
Supplemental non-cash financing and investing information:	'	'
Transfer of inventories to equipment	65	561
Stock issued for repayment of related party note payable	$187	$0

Basis_of_Presentation_and_Summ

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2014
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]	'
Basis of Presentation and Summary of Significant Accounting Policies	'
	1	Basis of Presentation and Summary of Significant Accounting Policies
	Organization and Basis of Presentation
	Cesca Therapeutics Inc. (the Company, we or our) is focused on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine.  We are a leader in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.  During the quarter ended March 31, 2014, Cesca Therapeutics Inc. was formed by the merger of ThermoGenesis Corp. and TotipotentRX.  See footnote 2 for details of the transaction.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Cesca Therapeutics Inc., and our wholly-owned subsidiaries, TotipotentRX Cell Therapy, Pvt. Ltd. and TotipotentSC Scientific Product Pvt. Ltd.  All significant intercompany accounts and transactions have been eliminated upon consolidation.
	Interim Reporting
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (SEC) rules and regulations and accounting principles applicable for interim periods.  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.  Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed financial statements through the date of issuance.  Operating results for the nine month period ended March 31, 2014, are not necessarily indicative of the results that may be expected for the year ending June 30, 2014.  These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended June 30, 2013.
	Revenue Recognition
	Revenues from the sale of our products and services are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured.  We generally ship products F.O.B. shipping point.  There is no conditional evaluation on any product sold and recognized as revenue.   Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet.
	Our sales are generally through distributors.  There is no right of return provided for distributors.  For sales of products made to distributors, we consider a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received.  These factors include, but are not limited to, whether the payment terms offered to the distributor are considered to be non-standard, the distributor history of adhering to the terms of its contractual arrangements with us, the level of inventories maintained by the distributor, whether we have a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive.  We currently recognize revenue primarily on the sell-in method with our distributors.
	Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis.  Revenue for each unit of accounting is recognized as the unit of accounting is delivered.  Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables.  Estimated selling prices are determined using vendor specific objective evidence of value (VSOE), when available, or an estimate of selling price when VSOE is not available for a given unit of accounting.  Significant inputs for the estimates of the selling price of separate units of accounting include market and pricing trends and a customer’s geographic location.  We account for training and installation, and service agreements and the collection, processing and testing of the umbilical cord blood and the storage as separate units of accounting.
	Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement.  Revenue generated from storage contracts is deferred and recorded ratably over the life of the agreement, up to 21 years.  All other service revenue is recognized at the time the service is completed.
	Revenues are net of normal discounts.  Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
	Foreign Currencies
	Our reporting currency is the US dollar.  The functional currency of our subsidiaries in India is the Indian rupee (INR). Assets and liabilities are translated into US dollars at period end exchange rates. Revenue and expenses are translated at average rates of exchange prevailing during the periods presented. Cash flows were also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows did not necessarily agree with changes in the corresponding balances on the consolidated balance sheet. Equity accounts other than retained earnings are translated at the historic exchange rate on the date of investment. A translation adjustment of $50,000 for the three and nine months ended March 31, 2014 resulting from this process is recorded as a component of other comprehensive income.
	Goodwill
	Goodwill is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate potential impairment.  Our goodwill evaluation is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value.  We assess qualitative factors to determine if our sole reporting unit’s fair value is more likely than not to exceed its carrying value, including goodwill.
	Intangible Assets
	Intangible assets are amortized over their estimated useful lives based on expected economic benefit with no residual value. Expenditures of costs to renew or extend the term of a recognized intangible asset and materially extend the useful life are capitalized. Clinical protocols are processes and procedures for a cell therapy for a particular indication. Clinical protocols are not expected to provide economic benefit until they are introduced to the marketplace.  We perform a test for impairment annually, or more frequently when indicators of impairment are present.
	Fair Value of Financial Instruments
	The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short duration.  At March 31, 2014, the Company had approximately $340,000 in cash equivalents classified as Level 1 assets, which are based on quoted market prices in active markets for identical assets and liabilities.
	Segment Reporting
	We have one reportable business segment:  the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine.
	Net Loss per Share
	Net loss per share is computed by dividing the net loss to common stockholders by the weighted average number of common shares outstanding.  The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented.  Anti-dilutive securities, which consist of stock options, common stock restricted awards and warrants, that were not included in diluted net loss per common share, were 4,741,159 and 2,596,503 as of March 31, 2014 and 2013, respectively.
	Recently Adopted Accounting Pronouncements
	In February 2013, the FASB issued ASC 2013-02, which is an update to improve the reporting of reclassifications out of accumulated other comprehensive income (AOCI).  Companies are also required to present reclassifications by component when reporting changes in AOCI balances.  We adopted ASC 2013-02 effective July 1, 2013.  The adoption of ASC 2013-02 did not have a material impact on our results of operations or financial condition.
	Recently Issued Accounting Pronouncements
	In March 2013, the FASB issued ASU 2013-05, “Foreign Currency Matters” (Topic 830) which provides guidance on a parent’s accounting for the cumulative translation adjustment upon de-recognition of a subsidiary or group of assets within a foreign entity.  This new guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided.  The new guidance will be effective for us beginning July 1, 2014.  We are currently assessing the potential impact, if any, the adoption of ASU 2013-05 may have on our consolidated financial statements.
	In July 2013, the FASB issued ASU 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”. This amendment requires entities to present an unrecognized tax benefit or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward or a similar tax loss or a tax credit carryforward, unless certain conditions exist. This guidance is effective prospectively for annual reporting periods (and the interim periods within) beginning after December 15, 2013. Early adoption and retrospective application are permitted. We expect to adopt this guidance effective July 2014.  We are currently assessing the potential impact, if any, the adoption of ASU 2013-11 may have on our consolidated financial statements.

Acquisition_of_Totipotent_RX

Acquisition of Totipotent RX	9 Months Ended
	Mar. 31, 2014
Acquisition of Totipotent RX [Abstract]	'
Acquisition of Totipotent RX	'
	2	Acquisition of Totipotent RX
	On February 18, 2014, the Company consummated the acquisition of TotipotentRX by merger pursuant to the Agreement and Plan of Merger and Reorganization (Merger Agreement).  TotipotentRX was a privately held biomedical technology company specializing in human clinical trials in the field of regenerative medicine and the exclusive provider of cell-based therapies to the Fortis Healthcare System.  TotipotentRX had two wholly-owned subsidiaries, TotipotentRX Cell Therapy Pvt. Ltd. (TotiRX India) and TotipotentSC Product Pvt. Ltd. (TotiSC India).  The two subsidiaries are located in Gurgaon, a suburb of New Delhi, India.  The Company believes that TotipotentRX has the depth of clinical, scientific and biological engineering experience necessary to fully engineer and effectively navigate the evolving regulatory pathways necessary to commercialize approved blockbuster cell therapies.  Subsequent to February 18, 2014 Cesca has recorded revenues of approximately $120,000 and net loss of approximately $60,000 for the quarter ended March 31, 2014 associated with the operations of TotipotentRX.
	The acquisition was accounted for under the acquisition method of accounting for business combinations in accordance with FASB ASC 805, Business Combinations, which requires, among other things that the assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date.  Acquisition-related costs are not included as a component of the acquisition accounting, but are recognized as expenses in the periods in which the costs are incurred. Acquisition related costs of $484,000 and $1,725,000 for the three and nine months ended were included in general and administrative expenses.  Any changes within the measurement period resulting from facts and circumstances that existed as of the acquisition date may result in retrospective adjustments to the provisional amounts recorded at the acquisition date.
	Pursuant to the Merger Agreement, TotipotentRX shareholders were issued in the aggregate 12,490,841 shares of the Company’s common stock, or 38% of the then outstanding common stock of the combined company, in exchange for all the TotipotentRX common stock outstanding and the Company assumed warrants of TotipotentRX representing the right to purchase approximately 61,020 shares of the Company’s common stock.  All outstanding stock options to purchase shares of the TotipotentRX common stock were exercised or cancelled.
	Preliminary Allocation of Consideration Transferred to Net Assets Acquired
	The following represents the consideration transferred to acquire TotipotentRX and its preliminary determination of the fair value of identifiable assets acquired and liabilities assumed at the acquisition date. The Company issued 12,490,841 shares of its common stock that had a total fair value of $27,105,000 based on the closing market price on February 18, 2014, the acquisition date.  The Company also issued 61,020 warrants, which are convertible into 61,020 shares of common stock that had a total fair value of $52,000 and $17,000 for the settlement of existing receivables and payables between the parties pre-merger. The clinical protocols and other intangible assets amounts are subject to change until their fair values are finalized.  Property and equipment is currently stated at its historical cost basis until its appropriate fair value is determined.  The Company acquired $232,000 gross contractual amounts receivable.  The difference between the gross contractual amount and the fair value of receivables is the best estimate of the contractual cash flows not expected to be collected.  The final determination of the fair value of certain assets and liabilities will be completed within the 12-month measurement period from the date of acquisition as required. Any potential adjustments made could be material in relation to the preliminary values presented below:
	Purchase Price:
	ThermoGenesis common shares and warrants					$	27,174,000
	Fair value of assets acquired:
	Cash		$	351,000
	Receivables			171,000
	Inventories			191,000
	Clinical protocols			6,041,000
	Other intangible assets			2,714,000
	Property and equipment			325,000
	Other assets			132,000
	Total assets			9,925,000
	Fair value of liabilities assumed:
	Accounts payable			627,000
	Related party notes payable			337,000
	Other liabilities			680,000
	Total liabilities		$	1,644,000
	Net assets acquired						8,281,000
	Preliminary goodwill					$	18,893,000
	Supplemental Pro Forma Data
	The Company used the acquisition method of accounting to account for the Totipotent RX acquisition and, accordingly, the results of TotipotentRX are included in the Company’s consolidated financial statements for the period subsequent to the date of acquisition.  The following unaudited supplemental pro forma data for the quarter and nine months ended March 31, 2014 and 2013 present consolidated information as if the acquisition had been completed on July 1, 2012.  The pro forma results were calculated by combining the results of ThermoGenesis Corp with the stand-alone results of Totipotent RX for the pre-acquisition periods:
			Three Months Ended						Nine Months Ended
			March 31,			March 31,			March 31,			March 31,
			2014			2013			2014			2013
	Net revenues		$	4,099,000		$	5,274,000		$	12,738,000		$	14,897,000
	Net loss		$	(1,702,000	)	$	(1,300,000	)	$	(5,139,000	)	$	(2,057,000	)
	The unaudited pro forma financial information reflects certain adjustments related to the acquisition, such as the incremental amortization expense in connection with recording acquired identifiable intangible assets at fair value, the incremental payroll expense associated with the new executive salaries resulting from the merger, and the elimination of the impact of historical transactions between ThermoGenesis and TotipotentRX that would have been treated as intercompany transactions had the companies been consolidated.  The unaudited pro forma financial information also excludes certain non-recurring expenses directly attributable to the merger in the amount of $531,000 and $1,933,000 for the three and nine months ended March 31, 2014, respectively, and $275,000 for the three and nine months ended March 31, 2013.
	Repayment of Related Party Notes Payable
	As of February 18, 2014, TotipotentRX owed $337,000 to two of its officers who have since joined the Company.  In the Merger Agreement, Cesca agreed to pay off the notes payable at closing as follows:  $75,000 cash to each officer for a total of $150,000 and the remainder in shares of common stock.  Approximately 82,000 shares of common stock were issued to satisfy the remainder of the debt.

Intangible_Assets

Intangible Assets	9 Months Ended
	Mar. 31, 2014
Intangible Asset [Abstract]	'
Intangible Assets	'
	3	Intangible Assets
	Intangible assets consist of the following based on our preliminary determination of the fair value of identifiable assets acquired (see footnote 2). Clinical protocols have not yet been introduced to the marketplace:
			31-Mar-14
			Weighted		Gross		Accumulated		Net
			Average		Carrying		Amortization
			Amortization		Amount
			Period
			(in Years)
	Trade names			7	$	324,000	$	6,000	$	318,000
	Licenses			7		354,000		7,000		347,000
	Customer relationships			3		439,000		19,000		420,000
	Device registration			7		141,000		3,000		138,000
	Covenants not to compete			5		1,456,000		36,000		1,420,000
	Clinical protocols					6,041,000		--		6,041,000
	Total				$	8,755,000	$	71,000	$	8,684,000
	Amortization of intangible assets was $71,000 for the three months ended March 31, 2014. Our estimated future amortization expense for years ended June 30, is as follows:
	Year Ended June 30,
	April 1 – June 30, 2014		$	139,000
	2015			555,000
	2016			555,000
	2017			499,000
	2018			408,000
	Thereafter			487,000
	Total		$	2,643,000

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	4	Commitments and Contingencies
	Financial Covenants
	In June 2010, we entered into a License and Escrow Agreement which granted a customer a non-exclusive, royalty-free license to certain intellectual property necessary for the potential manufacture and supply of AXP devices and certain AXP disposables.  The license is for the sole and limited purpose of manufacturing and supplying the AXP and related disposables for use by the customer.  The licensed intellectual property will be maintained in escrow and will be released to and used by the customer if and only if the Company defaults under the Agreement.  Originally, default occurred if the Company (1) fails to meet certain positive cash flow metrics for each rolling quarterly measurement period except where the following two measures are met, (2) failure to meet cash balance and short-term investments of at least $6,000,000 at the end of any given month, or (3) failure to meet a quick ratio of 2 to 1 at the end of any given month.
	On December 31, 2013, we amended and restated the License and Escrow Agreement to delete all of the financial covenants except the minimum cash and short-term investments balance covenant, (2) above, which was reduced to $2,000,000 at the end of any given month.  We are in compliance with this covenant at April 30, 2014.
	Contingencies
	On April 11, 2013, we filed an answer and counter-claims in response to the complaint Harvest Technologies Corp. (Harvest) filed on October 24, 2012 against the Company in the case captioned as Harvest Technologies Corp. v. ThermoGenesis Corp., 12-cv-01354, U.S. District Court, District of Delaware (Wilmington), with the complaint being amended on February 15, 2013 to name the Company’s customer Celling Technologies, LLC as a defendant.  In the complaint, Harvest contends that our Res-Q 60 System infringes certain Harvest patents. Our counter-claims are based on anti-trust and other alleged improper conduct by Harvest and further seek declarations that the Res-Q 60 System does not infringe the patents and that the patents are invalid.  The Company is vigorously defending itself against the Harvest claims, while aggressively pursuing its separate claims against Harvest.  The Company is unable to ascertain the likelihood of any liability and has not made an accrual for any potential losses as a result of the claims as of March 31, 2014.
	During the three months ended September 30, 2012, we were notified by a third party who believes that the Res-Q system infringes upon certain of its US and European patents.  The Company is unable to ascertain the likelihood of any liability and has not made an accrual as of March 31, 2014.
	Warranty
	We offer a warranty on all of our products of one to two years, except disposable products which we warrant through their expiration date.  We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.
	The warranty liability is included in other current liabilities in the unaudited balance sheet.  The change in the warranty liability for the nine months ended March 31, 2014 is summarized in the following table:
	Balance at July 1, 2013		$	489,000
	Warranties issued during the period			132,000
	Settlements made during the period			(88,000	)
	Changes in liability for pre-existing warranties during the period			(145,000	)
	Balance at March 31, 2014		$	388,000

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	5	Stockholders’ Equity
	Common Stock
	On January 30, 2014, the Company completed a private placement of the sale of 3,336,800 shares of its common stock at $2.00 per share, together with warrants to purchase up to an aggregate of 1,668,400 shares of common stock.  The warrants may be exercised by the holders at a price of $2.81 per share starting July 30, 2014 continuing through January 29, 2019.  Net proceeds after expenses from the offering were approximately $5.9 million.
	Warrants
	The following is a summary of warrant activity during the nine months ended March 31, 2014:
			Number of			Weighted
			Shares			Average
						Exercise Price
						Per Share
	Balance at June 30, 2013			1,125,000		$	2.64
	Warrants granted			1,729,420		$	2.79
	Outstanding at March 31, 2014			2,854,420		$	2.73
	Exercisable at March 31, 2014			1,186,020		$	2.61
	Stock Based Compensation
	We recorded stock-based compensation of $178,000 and $462,000 for the three and nine months ended March 31, 2014, and $138,000 and $410,000 for the three and nine months ended March 31, 2013.
	The following is a summary of option activity for our stock option plans:
			Number of			Weighted-		Weighted-		Aggregate
			Shares			Average		Average		Intrinsic
						Exercise		Remaining		Value
						Price		Contractual
								Life
	Outstanding at June 30, 2013			1,063,750		$	2.36
	Granted			419,735		$	2.08
	Exercised			(9,375	)	$	2.32
	Forfeited			(23,625	)	$	2.28
	Expired			(191,250	)	$	3.43
	Outstanding at March 31, 2014			1,259,235		$	2.11		2.7	$	231,000
	Vested and Expected to Vest at March 31, 2014			1,067,000		$	2.05		2.4	$	195,000
	Exercisable at March 31, 2014			587,007		$	2.4		1.5	$	85,000
	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the 327,500 options that were in the money at March 31, 2014.  During the nine months ended March 31, 2014, the aggregate intrinsic value of options exercised under the Company’s stock option plans was $4,000.  There were no options exercised during the nine months ended March 31, 2013.
	Common Stock Restricted Awards
	The following is a summary of restricted stock activity during the nine months ended March 31, 2014:
						Weighted
						Average
			Number of			Grant Date
			Shares			Fair Value
	Balance at June 30, 2013			390,003		$	1.81
	Granted			452,500		$	2.18
	Vested			(181,665	)	$	1.84
	Forfeited			(33,334	)	$	1.81
	Outstanding at March 31, 2014			627,504		$	2.07
	In connection with the vesting of the restricted stock awards, the election was made by some of the employees to satisfy the applicable federal income tax withholding obligation by a net share settlement, pursuant to which the Company withheld 57,680 shares and used the deemed proceeds from those shares to pay the income tax withholding.  The net share settlement is deemed to be a repurchase by the Company of its common stock.

Sale_of_Product_Lines

Sale of Product Lines	9 Months Ended
	Mar. 31, 2014
Sale of Product Lines [Abstract]	'
Sale of Product Lines	'
	6	Sale of Product Lines
	ThermoLine
	On December 31, 2012, the Company entered into an Asset Purchase Agreement for the sale of certain of the assets, rights and properties of the ThermoLine product line for $500,000.  The $500,000 was received upon signing the agreement and was included in other current liabilities on the December 31, 2012 balance sheet.  The Company recognized the gain on sale upon delivery of the assets which occurred during the quarter ended March 31, 2013.
	CryoSeal
	In June 2010, the Company and Asahi entered into an amendment (the "Amendment") of their Distribution and License Agreement.  Under the terms of the Amendment, Asahi obtained exclusive rights to distribute the CryoSeal System in South Korea, North Korea, Taiwan, the People’s Republic of China, the Philippines, Thailand, Singapore, India and Malaysia. These rights included the exclusive right to market, distribute and sell the processing disposables and Thrombin Reagent for production of thrombin in a stand-alone product.
	In connection with the above-described Amendment, the Company and Asahi also entered into an Option Agreement ("Option Agreement") and on June 30, 2012, Asahi exercised the option to purchase certain intangible assets related to this product line, including all associated patents and engineering files for $2,000,000.  In connection with the notice of exercise, the Amendment automatically terminated.  Payment of the $2,000,000 was based upon completion of certain provisions of the Option Agreement.  As such, the Company recognized the gain on sale upon completion of those provisions which occurred in July 2012.  The $2,000,000 payment was received in August 2012.

Subsequent_Event

Subsequent Event	9 Months Ended
	Mar. 31, 2014
Subsequent Event [Abstract]	'
Subsequent Event	'
	7	Subsequent Event
	In April 2014, the Company signed a three year operating lease for a facility in Emeryville, California with lease payments of approximately $16,000 a month.

Basis_of_Presentation_and_Summ1

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2014
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]	'
Organization and Basis of Presentation	'
	Organization and Basis of Presentation
	Cesca Therapeutics Inc. (the Company, we or our) is focused on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine.  We are a leader in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.  During the quarter ended March 31, 2014, Cesca Therapeutics Inc. was formed by the merger of ThermoGenesis Corp. and TotipotentRX.  See footnote 2 for details of the transaction.
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Cesca Therapeutics Inc., and our wholly-owned subsidiaries, TotipotentRX Cell Therapy, Pvt. Ltd. and TotipotentSC Scientific Product Pvt. Ltd.  All significant intercompany accounts and transactions have been eliminated upon consolidation.
Interim Reporting	'
	Interim Reporting
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (SEC) rules and regulations and accounting principles applicable for interim periods.  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.  Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed financial statements through the date of issuance.  Operating results for the nine month period ended March 31, 2014, are not necessarily indicative of the results that may be expected for the year ending June 30, 2014.  These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended June 30, 2013.
Revenue Recognition	'
	Revenue Recognition
	Revenues from the sale of our products and services are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured.  We generally ship products F.O.B. shipping point.  There is no conditional evaluation on any product sold and recognized as revenue.   Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet.
	Our sales are generally through distributors.  There is no right of return provided for distributors.  For sales of products made to distributors, we consider a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received.  These factors include, but are not limited to, whether the payment terms offered to the distributor are considered to be non-standard, the distributor history of adhering to the terms of its contractual arrangements with us, the level of inventories maintained by the distributor, whether we have a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive.  We currently recognize revenue primarily on the sell-in method with our distributors.
	Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis.  Revenue for each unit of accounting is recognized as the unit of accounting is delivered.  Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables.  Estimated selling prices are determined using vendor specific objective evidence of value (VSOE), when available, or an estimate of selling price when VSOE is not available for a given unit of accounting.  Significant inputs for the estimates of the selling price of separate units of accounting include market and pricing trends and a customer’s geographic location.  We account for training and installation, and service agreements and the collection, processing and testing of the umbilical cord blood and the storage as separate units of accounting.
	Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement.  Revenue generated from storage contracts is deferred and recorded ratably over the life of the agreement, up to 21 years.  All other service revenue is recognized at the time the service is completed.
	Revenues are net of normal discounts.  Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Foreign Currencies	'
	Foreign Currencies
	Our reporting currency is the US dollar.  The functional currency of our subsidiaries in India is the Indian rupee (INR). Assets and liabilities are translated into US dollars at period end exchange rates. Revenue and expenses are translated at average rates of exchange prevailing during the periods presented. Cash flows were also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows did not necessarily agree with changes in the corresponding balances on the consolidated balance sheet. Equity accounts other than retained earnings are translated at the historic exchange rate on the date of investment. A translation adjustment of $50,000 for the three and nine months ended March 31, 2014 resulting from this process is recorded as a component of other comprehensive income.
Goodwill	'
	Goodwill
	Goodwill is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate potential impairment.  Our goodwill evaluation is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value.  We assess qualitative factors to determine if our sole reporting unit’s fair value is more likely than not to exceed its carrying value, including goodwill.
Intangible Assets	'
	Intangible Assets
	Intangible assets are amortized over their estimated useful lives based on expected economic benefit with no residual value. Expenditures of costs to renew or extend the term of a recognized intangible asset and materially extend the useful life are capitalized. Clinical protocols are processes and procedures for a cell therapy for a particular indication. Clinical protocols are not expected to provide economic benefit until they are introduced to the marketplace.  We perform a test for impairment annually, or more frequently when indicators of impairment are present.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short duration.  At March 31, 2014, the Company had approximately $340,000 in cash equivalents classified as Level 1 assets, which are based on quoted market prices in active markets for identical assets and liabilities.
Segment Reporting	'
	Segment Reporting
	We have one reportable business segment:  the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine.
Net Loss per Share	'
	Net Loss per Share
	Net loss per share is computed by dividing the net loss to common stockholders by the weighted average number of common shares outstanding.  The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented.  Anti-dilutive securities, which consist of stock options, common stock restricted awards and warrants, that were not included in diluted net loss per common share, were 4,741,159 and 2,596,503 as of March 31, 2014 and 2013, respectively.
Recently Adopted Accounting Pronouncements	'
	Recently Adopted Accounting Pronouncements
	In February 2013, the FASB issued ASC 2013-02, which is an update to improve the reporting of reclassifications out of accumulated other comprehensive income (AOCI).  Companies are also required to present reclassifications by component when reporting changes in AOCI balances.  We adopted ASC 2013-02 effective July 1, 2013.  The adoption of ASC 2013-02 did not have a material impact on our results of operations or financial condition.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	In March 2013, the FASB issued ASU 2013-05, “Foreign Currency Matters” (Topic 830) which provides guidance on a parent’s accounting for the cumulative translation adjustment upon de-recognition of a subsidiary or group of assets within a foreign entity.  This new guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided.  The new guidance will be effective for us beginning July 1, 2014.  We are currently assessing the potential impact, if any, the adoption of ASU 2013-05 may have on our consolidated financial statements.
	In July 2013, the FASB issued ASU 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”. This amendment requires entities to present an unrecognized tax benefit or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward or a similar tax loss or a tax credit carryforward, unless certain conditions exist. This guidance is effective prospectively for annual reporting periods (and the interim periods within) beginning after December 15, 2013. Early adoption and retrospective application are permitted. We expect to adopt this guidance effective July 2014.  We are currently assessing the potential impact, if any, the adoption of ASU 2013-11 may have on our consolidated financial statements.

Acquisition_of_Totipotent_RX_T

Acquisition of Totipotent RX (Tables)	9 Months Ended
	Mar. 31, 2014
Acquisition of Totipotent RX [Abstract]	'
Schedule of purchase price allocation	'
	Preliminary Allocation of Consideration Transferred to Net Assets Acquired
	The following represents the consideration transferred to acquire TotipotentRX and its preliminary determination of the fair value of identifiable assets acquired and liabilities assumed at the acquisition date. The Company issued 12,490,841 shares of its common stock that had a total fair value of $27,105,000 based on the closing market price on February 18, 2014, the acquisition date.  The Company also issued 61,020 warrants, which are convertible into 61,020 shares of common stock that had a total fair value of $52,000 and $17,000 for the settlement of existing receivables and payables between the parties pre-merger. The clinical protocols and other intangible assets amounts are subject to change until their fair values are finalized.  Property and equipment is currently stated at its historical cost basis until its appropriate fair value is determined.  The Company acquired $232,000 gross contractual amounts receivable.  The difference between the gross contractual amount and the fair value of receivables is the best estimate of the contractual cash flows not expected to be collected.  The final determination of the fair value of certain assets and liabilities will be completed within the 12-month measurement period from the date of acquisition as required. Any potential adjustments made could be material in relation to the preliminary values presented below:
	Purchase Price:
	ThermoGenesis common shares and warrants				$	27,174,000
	Fair value of assets acquired:
	Cash	$	351,000
	Receivables		171,000
	Inventories		191,000
	Clinical protocols		6,041,000
	Other intangible assets		2,714,000
	Property and equipment		325,000
	Other assets		132,000
	Total assets		9,925,000
	Fair value of liabilities assumed:
	Accounts payable		627,000
	Related party notes payable		337,000
	Other liabilities		680,000
	Total liabilities	$	1,644,000
	Net assets acquired					8,281,000
	Preliminary goodwill				$	18,893,000
Business acquisition, pro forma information	'
	Supplemental Pro Forma Data
	The Company used the acquisition method of accounting to account for the Totipotent RX acquisition and, accordingly, the results of TotipotentRX are included in the Company’s consolidated financial statements for the period subsequent to the date of acquisition.  The following unaudited supplemental pro forma data for the quarter and nine months ended March 31, 2014 and 2013 present consolidated information as if the acquisition had been completed on July 1, 2012.  The pro forma results were calculated by combining the results of ThermoGenesis Corp with the stand-alone results of Totipotent RX for the pre-acquisition periods:
		Three Months Ended						Nine Months Ended
		March 31,			March 31,			March 31,			March 31,
		2014			2013			2014			2013
	Net revenues	$	4,099,000		$	5,274,000		$	12,738,000		$	14,897,000
	Net loss	$	(1,702,000	)	$	(1,300,000	)	$	(5,139,000	)	$	(2,057,000	)

Intangible_Assets_Tables

Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2014
Intangible Asset [Abstract]	'
Schedule of intangible assets	'
	Intangible assets consist of the following based on our preliminary determination of the fair value of identifiable assets acquired (see footnote 2). Clinical protocols have not yet been introduced to the marketplace:
		31-Mar-14
		Weighted		Gross		Accumulated		Net
		Average		Carrying		Amortization
		Amortization		Amount
		Period
		(in Years)
	Trade names		7	$	324,000	$	6,000	$	318,000
	Licenses		7		354,000		7,000		347,000
	Customer relationships		3		439,000		19,000		420,000
	Device registration		7		141,000		3,000		138,000
	Covenants not to compete		5		1,456,000		36,000		1,420,000
	Clinical protocols				6,041,000		--		6,041,000
	Total			$	8,755,000	$	71,000	$	8,684,000
Schedule of future amortization expense	'
	Amortization of intangible assets was $71,000 for the three months ended March 31, 2014. Our estimated future amortization expense for years ended June 30, is as follows:
	Year Ended June 30,
	April 1 – June 30, 2014	$	139,000
	2015		555,000
	2016		555,000
	2017		499,000
	2018		408,000
	Thereafter		487,000
	Total	$	2,643,000

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
Schedule of changes in warrant liability included in accrued liabilities	'
	The warranty liability is included in other current liabilities in the unaudited balance sheet.  The change in the warranty liability for the nine months ended March 31, 2014 is summarized in the following table:
	Balance at July 1, 2013	$	489,000
	Warranties issued during the period		132,000
	Settlements made during the period		(88,000	)
	Changes in liability for pre-existing warranties during the period		(145,000	)
	Balance at March 31, 2014	$	388,000

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
Warrant activity	'
	The following is a summary of warrant activity during the nine months ended March 31, 2014:
		Number of			Weighted
		Shares			Average
					Exercise Price
					Per Share
	Balance at June 30, 2013		1,125,000		$	2.64
	Warrants granted		1,729,420		$	2.79
	Outstanding at March 31, 2014		2,854,420		$	2.73
	Exercisable at March 31, 2014		1,186,020		$	2.61
Option activity for stock option plans	'
	The following is a summary of option activity for our stock option plans:
		Number of			Weighted-		Weighted-		Aggregate
		Shares			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Life
	Outstanding at June 30, 2013		1,063,750		$	2.36
	Granted		419,735		$	2.08
	Exercised		(9,375	)	$	2.32
	Forfeited		(23,625	)	$	2.28
	Expired		(191,250	)	$	3.43
	Outstanding at March 31, 2014		1,259,235		$	2.11		2.7	$	231,000
	Vested and Expected to Vest at March 31, 2014		1,067,000		$	2.05		2.4	$	195,000
	Exercisable at March 31, 2014		587,007		$	2.4		1.5	$	85,000
Restricted stock activity granted to employees	'
	The following is a summary of restricted stock activity during the nine months ended March 31, 2014:
					Weighted
					Average
		Number of			Grant Date
		Shares			Fair Value
	Balance at June 30, 2013		390,003		$	1.81
	Granted		452,500		$	2.18
	Vested		(181,665	)	$	1.84
	Forfeited		(33,334	)	$	1.81
	Outstanding at March 31, 2014		627,504		$	2.07

Basis_of_Presentation_and_Summ2

Basis of Presentation and Summary of Significant Accounting Policies (Details) (USD $)	9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
	Segment
Revenue Recognition [Abstract]	'	'
Maximum period of agreement	'21 years	'
Foreign Currencies [Abstract]	'	'
Foreign currency translation adjustments	$50,000	'
Segment Reporting [Abstract]	'	'
Number of reportable segments	1	'
Net Loss per Share [Abstract]	'	'
Anti-dilutive securities not included in diluted net loss per common share (in shares)	4,741,159	2,596,503
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	$340,000	'

Acquisition_of_Totipotent_RX_D

Acquisition of Totipotent RX (Details) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 28, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Feb. 18, 2014
					Subsidiary		Officer
Business Acquisition [Line Items]	'	'	'	'	'	'	'
Acquisition related costs	'	'	$484,000	'	$1,725,000	'	'
Number of convertible shares in exchange of warrants issued (in shares)	'	1,668,400	1,668,400	'	1,668,400	'	'
Business Acquisition, Pro Forma Information [Abstract]	'	'	'	'	'	'	'
Repayment of related party notes payable	'	'	'	'	150,000	0	'
TotipotentRX Corporation [Member]	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'
Number of wholly owned subsidiaries	'	'	'	'	2	'	'
Recorded revenues during the quarter	'	120,000	'	'	'	'	'
Recorded loss during the quarter	'	60,000	'	'	'	'	'
Aggregate number of shares issued (in shares)	12,490,841	'	'	'	'	'	'
Percentage of common stock issued to acquiree shareholders (in hundredths)	'	'	'	'	'	'	38.00%
Fair value of aggregate number of shares issued	'	'	'	'	'	'	27,105,000
Number of convertible shares in exchange of warrants issued (in shares)	'	'	'	'	'	'	61,020
Warrant issued in relation to business acquisition (in shares)	'	'	'	'	'	'	61,020
Fair value of common stock in exchange of warrants issued	'	'	'	'	'	'	52,000
Purchase Price [Abstract]	'	'	'	'	'	'	'
ThermoGenesis common shares and warrants	'	'	'	'	'	'	27,174,000
Fair value of assets acquired [Abstract]	'	'	'	'	'	'	'
Cash	'	'	'	'	'	'	351,000
Receivables	'	'	'	'	'	'	171,000
Inventories	'	'	'	'	'	'	191,000
Clinical protocols	'	'	'	'	'	'	6,041,000
Other intangible assets	'	'	'	'	'	'	2,714,000
Property and equipment	'	'	'	'	'	'	325,000
Other assets	'	'	'	'	'	'	132,000
Total assets	'	'	'	'	'	'	9,925,000
Fair value of liabilities assumed [Abstract]	'	'	'	'	'	'	'
Accounts payable	'	'	'	'	'	'	627,000
Related party notes payable	'	'	'	'	'	'	337,000
Other liabilities	'	'	'	'	'	'	680,000
Total liabilities	'	'	'	'	'	'	1,644,000
Net assets acquired	'	'	'	'	'	'	8,281,000
Preliminary goodwill	'	'	'	'	'	'	18,893,000
Business Acquisition, Pro Forma Information [Abstract]	'	'	'	'	'	'	'
Net revenues	'	'	4,099,000	5,274,000	12,738,000	14,897,000	'
Net loss	'	'	-1,702,000	-1,300,000	-5,139,000	-2,057,000	'
Non-recurring expenses directly attributable to the merger	'	'	531,000	275,000	1,933,000	275,000	'
Settlement of receivables and payables between merging companies	'	'	'	'	'	'	17,000
Gross contractual amounts receivable	'	'	'	'	'	'	232,000
Number of officers whom repayment of notes payable	'	'	'	'	'	'	2
Repayment of each officer notes payable	'	'	'	'	75,000	'	'
Repayment of related party notes payable	'	'	'	'	$150,000	'	'
Shares issued to satisfy the remainder of debt (in shares)	'	'	'	'	'	'	82,000

Intangible_Asset_Details

Intangible Asset (Details) (USD $)	9 Months Ended
	Mar. 31, 2014
Finite-Lived Intangible Assets [Line Items]	'
Gross Carrying Amount	$8,755,000
Accumulated Amortization	71,000
Net	8,684,000
Estimated future amortization expense [Abstract]	'
April 1 - June 30, 2014	139,000
2015	555,000
2016	555,000
2017	499,000
2018	408,000
Thereafter	487,000
Total	2,643,000
Trade names [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Weighted Average Amortization Period (in Years)	'7 years
Gross Carrying Amount	324,000
Accumulated Amortization	6,000
Net	318,000
Licenses [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Weighted Average Amortization Period (in Years)	'7 years
Gross Carrying Amount	354,000
Accumulated Amortization	7,000
Net	347,000
Customer relationships [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Weighted Average Amortization Period (in Years)	'3 years
Gross Carrying Amount	439,000
Accumulated Amortization	19,000
Net	420,000
Device registration [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Weighted Average Amortization Period (in Years)	'7 years
Gross Carrying Amount	141,000
Accumulated Amortization	3,000
Net	138,000
Covenants not to compete [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Weighted Average Amortization Period (in Years)	'5 years
Gross Carrying Amount	1,456,000
Accumulated Amortization	36,000
Net	1,420,000
Clinical protocols [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Gross Carrying Amount	6,041,000
Accumulated Amortization	0
Net	$6,041,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	9 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Jun. 30, 2010
License and Escrow Agreement [Abstract]	'	'	'
Minimum cash balance and short-term investments	'	$2,000,000	$6,000,000
Warranty [Abstract]	'	'	'
Period of warranty on products, minimum	'1 year	'	'
Period of warranty on products, maximum	'2 years	'	'
Schedule of changes in product liability included in accrued liabilities [Roll Forward]	'	'	'
Balance at July 1, 2013	489,000	'	'
Warranties issued during the period	132,000	'	'
Settlements made during the period	-88,000	'	'
Changes in liability for pre-existing warranties during the period	-145,000	'	'
Balance at March 31, 2014	$388,000	'	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Common stock in public offering (in shares)	'	'	3,336,800	'
Purchase price of common stock issued (in dollars per share)	'	'	$2	'
Warrants to purchase common stock (in shares)	1,668,400	'	1,668,400	'
Exercise price of warrants (in dollars per share)	$2.81	'	$2.81	'
Net proceeds after expenses from offering	'	'	$5,944,000	$0
Stock Compensation Expense [Abstract]	'	'	'	'
Stock based compensation expense	178,000	138,000	462,000	410,000
Aggregate Intrinsic Value [Abstract]	'	'	'	'
Number of options for aggregate intrinsic value (in shares)	327,500	'	327,500	'
Weighted-Average Grant Date Fair Value [Roll Forward]	'	'	'	'
Number of shares withheld to pay income tax withholding (in shares)	'	'	57,680	'
Stock Options [Member]	'	'	'	'
Number of Shares [Roll Forward]	'	'	'	'
Outstanding at June 30, 2013 (in shares)	'	'	1,063,750	'
Granted (in shares)	'	'	419,735	'
Exercised (in shares)	'	'	-9,375	0
Forfeited (in shares)	'	'	-23,625	'
Expired (in shares)	'	'	-191,250	'
Outstanding at March 31, 2014 (in shares)	1,259,235	'	1,259,235	'
Vested and Expected to Vest at March 31, 2014 (in shares)	1,067,000	'	1,067,000	'
Exercisable at March 31, 2014 (in shares)	587,007	'	587,007	'
Weighted-Average Exercise Price Per Share [Roll Forward]	'	'	'	'
Balance at June 30, 2013 (in dollars per share)	'	'	$2.36	'
Granted (in dollars per share)	'	'	$2.08	'
Exercised (in dollars per share)	'	'	$2.32	'
Forfeited (in dollars per share)	'	'	$2.28	'
Expired (in dollars per share)	'	'	$3.43	'
Outstanding at March 31, 2014 (in dollars per share)	$2.11	'	$2.11	'
Vested and Expected to Vest at March 31, 2014 (in dollars per share)	$2.05	'	$2.05	'
Exercisable at March 31, 2014 (in dollars per share)	$2.40	'	$2.40	'
Weighted-Average Remaining Contractual Life [Abstract]	'	'	'	'
Outstanding at March 31, 2014	'	'	'2 years 8 months 12 days	'
Vested and Expected to Vest at March 31, 2014	'	'	'2 years 4 months 24 days	'
Exercisable at March 31, 2014	'	'	'1 year 6 months	'
Aggregate Intrinsic Value [Abstract]	'	'	'	'
Outstanding at March 31, 2014	231,000	'	231,000	'
Vested and Expected to Vest at March 31, 2014	195,000	'	195,000	'
Exercisable at March 31, 2014	85,000	'	85,000	'
Aggregate intrinsic value of options exercised	'	'	$4,000	'
Restricted Stock [Member]	'	'	'	'
Number of Shares [Roll Forward]	'	'	'	'
Balance at June 30, 2013 (in shares)	'	'	390,003	'
Granted (in shares)	'	'	452,500	'
Vested (in shares)	'	'	-181,665	'
Forfeited (in shares)	'	'	-33,334	'
Outstanding at March 31, 2014 (in shares)	627,504	'	627,504	'
Weighted-Average Grant Date Fair Value [Roll Forward]	'	'	'	'
Balance at June 30, 2013 (in dollars per share)	'	'	$1.81	'
Granted (in dollars per share)	'	'	$2.18	'
Vested (in dollars per share)	'	'	$1.84	'
Forfeited (in dollars per share)	'	'	$1.81	'
Outstanding at March 31, 2014 (in dollars per share)	$2.07	'	$2.07	'
Warrants [Member]	'	'	'	'
Number of Shares [Roll Forward]	'	'	'	'
Balance at June 30 (in shares)	'	'	1,125,000	'
Warrants granted (in shares)	'	'	1,729,420	'
Outstanding at March 31, 2014 (in shares)	2,854,420	'	2,854,420	'
Exercisable at March 31, 2014 (in shares)	1,186,020	'	1,186,020	'
Weighted-Average Exercise Price Per Share [Roll Forward]	'	'	'	'
Balance at June 30 (in dollars per share)	'	'	$2.64	'
Warrants granted (in dollars per share)	'	'	$2.79	'
Outstanding at March 31, 2014 (in dollars per share)	$2.73	'	$2.73	'
Exercisable at March 31, 2014 (in dollars per share)	$2.61	'	$2.61	'

Sale_of_Product_Lines_Details

Sale of Product Lines (Details) (USD $)	2 Months Ended		6 Months Ended
	Aug. 31, 2012	Jun. 30, 2012	Dec. 31, 2012
	Cryo Seal [Member]	Cryo Seal [Member]	ThermoLine [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'
Option agreement amount	'	$2,000,000	'
Payments received	2,000,000	'	'
Proceeds from the prepayment from sale of product line	'	'	$500,000

Subsequent_Event_Details

Subsequent Event (Details) (Subsequent Event [Member], USD $)	1 Months Ended
	Apr. 30, 2014
Subsequent Event [Member]	'
Subsequent Events [Line Items]	'
Term of lease	'3 years
Lease payments per month	$16,000